FCCC LOGO Faculty Publications
Chen X , Weaver J , Bove BA , Vanderveer LA , Weil SC , Miron A , Daly MB , Godwin AK
Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk
Hum Mol Genet. 2008 May 1;17(9) :1336-48
Back to previous list
The contribution of BRCA1 and BRCA2 to familial and non-familial forms of breast cancer has been difficult to accurately estimate because of the myriad of potential genetic and epigenetic mechanisms that can ultimately influence their expression and involvement in cellular activities. As one of these potential mechanisms, we investigated whether allelic imbalance (AI) of BRCA1 or BRCA2 expression was associated with an increased risk of developing breast cancer. By developing a quantitative approach utilizing allele-specific real-time PCR, we first evaluated AI caused by nonsense-mediated mRNA decay in patients with frameshift mutations in BRCA1 and BRCA2. We next measured AI for BRCA1 and BRCA2 in lymphocytes from three groups: familial breast cancer patients, non-familial breast cancer patients and age-matched cancer-free females. The AI ratios of BRCA1, but not BRCA2, in the lymphocytes from familial breast cancer patients were found to be significantly increased as compared to cancer-free women (BRCA1: 0.424 versus 0.211, P = 0.00001; BRCA2: 0.206 versus 0.172, P = 0.38). Similarly, the AI ratios were greater for BRCA1 and BRCA2 in the lymphocytes of non-familial breast cancer cases versus controls (BRCA1: 0.353, P = 0.002; BRCA2: 0.267, P = 0.03). Furthermore, the distribution of under-expressed alleles between cancer-free controls and familial cases was significantly different for both BRCA1 and BRCA2 gene expression (P < 0.02 and P < 0.02, respectively). In conclusion, we have found that AI affecting BRCA1 and to a lesser extent BRCA2 may contribute to both familial and non-familial forms of breast cancer.
Chen, Xiaowei Weaver, Joellen Bove, Betsy A Vanderveer, Lisa A Weil, Susan C Miron, Alexander Daly, Mary B Godwin, Andrew K P50 CA83638/CA/United States NCI R25 CA057708/CA/United States NCI U01 CA69631/CA/United States NCI Clinical Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. England Human molecular genetics Hum Mol Genet. 2008 May 1;17(9):1336-48. Epub 2008 Jan 19.